Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.
Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with e.g. with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases and with Celgene in the field of neurodegenerative diseases.
Evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional operating sites exist in Abingdon and Manchester, UK, Goettingen and Munich, Germany, Verona, Italy, Branford, Princeton and Watertown, USA, Basel, CH as well as Lyon and Toulouse, France. Evotec has more than 2,500 employees worldwide.